Detalhe da pesquisa
1.
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.
Cell
; 173(7): 1770-1782.e14, 2018 06 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29906450
2.
The current state of molecular testing in the treatment of patients with solid tumors, 2019.
CA Cancer J Clin
; 69(4): 305-343, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31116423
3.
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
Prostate
; 84(3): 292-302, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37964482
4.
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial.
Lancet
; 402(10407): 1043-1051, 2023 09 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37524096
5.
A Ten Year Experience of Men's Health Events in a Socioeconomically Diverse City in the United States - Lessons Learned.
J Community Health
; 2024 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38643316
6.
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study.
Lancet Oncol
; 24(5): 553-562, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37011650
7.
18 F-sodium fluoride positron emission tomography quantitation of bone metastases in African American and non-African American men with metastatic prostate cancer.
Prostate
; 83(12): 1193-1200, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37211866
8.
Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers.
Cancer
; 129(24): 3884-3893, 2023 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37565840
9.
Alcohol dehydrogenase expression patterns in normal prostate, benign prostatic hyperplasia, and prostatic adenocarcinoma in African American and Caucasian men.
Prostate
; 82(6): 666-675, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35133686
10.
Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on Race.
Oncologist
; 27(10): e815-e818, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36036607
11.
Phase Ia dose escalation study of OBP-801, a cyclic depsipeptide class I histone deacetylase inhibitor, in patients with advanced solid tumors.
Invest New Drugs
; 40(2): 300-307, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34613570
12.
Genomic correlates of clinical outcome in advanced prostate cancer.
Proc Natl Acad Sci U S A
; 116(23): 11428-11436, 2019 06 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31061129
13.
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV201): a multicentre, single-arm, phase 2 trial.
Lancet Oncol
; 22(6): 872-882, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33991512
14.
A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.
Cancer
; 127(16): 2954-2965, 2021 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33951180
15.
Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells.
Int J Mol Sci
; 22(13)2021 Jun 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34206543
16.
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.
Lancet Oncol
; 20(10): 1432-1443, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31515154
17.
Tackling tumor heterogeneity and phenotypic plasticity in cancer precision medicine: our experience and a literature review.
Cancer Metastasis Rev
; 37(4): 655-663, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30484007
18.
A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer.
Invest New Drugs
; 37(5): 1052-1060, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30725389
19.
A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).
BMC Cancer
; 19(1): 572, 2019 Jun 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31196032
20.
Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis.
Mol Cancer
; 15(1): 68, 2016 11 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27809841